Home/Filings/4/0000950170-24-128153
4//SEC Filing

Patel Sandip I 4

Accession 0000950170-24-128153

CIK 0001834645other

Filed

Nov 17, 7:00 PM ET

Accepted

Nov 18, 6:55 PM ET

Size

17.3 KB

Accession

0000950170-24-128153

Insider Transaction Report

Form 4
Period: 2024-11-14
Transactions
  • Disposition to Issuer

    Common Stock

    2024-11-1467,7350 total(indirect: See footnote)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-11-14400,0000 total
    Exercise: $0.80Common Stock (400,000 underlying)
  • Disposition to Issuer

    Common Stock

    2024-11-1468,8910 total(indirect: See footnote)
  • Conversion

    Common Stock

    2024-11-14+763,316763,316 total
  • Disposition to Issuer

    Common Stock

    2024-11-14763,3160 total
  • Disposition to Issuer

    Common Stock

    2024-11-1447,3640 total(indirect: See footnote)
  • Conversion

    Convertible Notes

    2024-11-140 total
    Common Stock (763,316 underlying)
Footnotes (7)
  • [F1]This Form 4 reports securities transacted pursuant to the terms of the Agreement and Plan of Merger, dated as of March 4, 2024, as amended (the "Merger Agreement"), by and among the Issuer, Akari Therapeutics Plc ("Parent"), and Pegasus Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer effective as of November 14, 2024, with the Issuer surviving as a wholly owned subsidiary of Parent (the "Merger").
  • [F2]Immediately prior to the effective time of the Merger (the "Effective Time"), the principal amount of convertible promissory notes held by the Reporting Person (together with accrued interest thereon) automatically converted into shares of common stock of the Issuer ("Peak Common Stock").
  • [F3]At the Effective Time, each issued and outstanding share of Peak Common Stock was cancelled and converted into the right to receive 0.2935 (the "Exchange Ratio") American Depositary Shares ("ADSs") of Parent, each ADS representing a number of ordinary shares, par value $0.0001 per share (the "Ordinary Shares") of Parent.
  • [F4]The securities are held by QuestBio LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
  • [F5]The securities are held by Davis Island Ventures, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
  • [F6]The securities are held by Innovative Lifesci Investments, LLC. The Reporting Person is managing member of the LLC and has sole dispositive power over the shares.
  • [F7]At the Effective Time, each option to purchase shares of Peak Common Stock ("Peak Option") that was outstanding immediately prior to the Effective Time and unexercised, whether or not vested, was assumed by Parent and converted into the option to purchase a number of Ordinary Shares or ADSs (any such option, an "Assumed Option") equal to the number of Peak Common Stock underlying each such Peak Option multiplied by the Exchange Ratio.

Documents

1 file

Issuer

Peak Bio, Inc.

CIK 0001834645

Entity typeother

Related Parties

1
  • filerCIK 0001843601

Filing Metadata

Form type
4
Filed
Nov 17, 7:00 PM ET
Accepted
Nov 18, 6:55 PM ET
Size
17.3 KB